Increasing evidence shows that abnormal microRNAs (miRNAs) expression is involved in tumorigenesis. They might be the novel biomarkers or therapeutic targets in disease treatment. miR-29 family was previously reported to act as tumor suppressors or oncogenes in diverse cancers. However, their accurate expression, function and mechanism in gastric cancer (GC) are not well known. Here, we found that the expression of miR-29 family members was significantly reduced in GC compared with adjacent controls. Among them, miR-29c had the most reduced percentage in GC and was associated with aggressive and progressive phenotypes of GC. We further demonstrated that miR-29 family acted as tumor suppressors through targeting CCND2 and matrix metalloproteinase-2 genes in GC. Moreover, the inverse relationship between miR-29 family and their targets was verified in patients and xenograft mice. Finally, reintroduction of miR-29 family significantly inhibited tumor formation of GC cells in the xenograft mice. Take together, our finding characterized the expression properties of miR-29 family, contributed to the function and molecular mechanism of miR-29 family in GC and implied that miR-29 family might be employed as novel prognostic markers and therapeutic targets of GC.
Introduction
Gastric cancer (GC) is one of the most common cancers and the leading cause of cancer-related death globally. Adenocarcinomas represent the vast majority of GC, whereas the remaining cases comprise non-Hodgkin lymphomas, sarcomas and carcinoid tumors. The incidence of GC varies depending on the geographic region, diet, and genetic background (1) . According to the National Cancer Institute, the incidence of GC is highest in Japan, South American and Eastern Europe and part of Middle East (2) . In China, the incidence of GC is still high despite advances in treatment and subsequent improvement in prognosis. However, in the West, where the incidence has continuously decreased, the overall and stage-specific survival is worse than that in Eastern Asia (3) . GC is twice more frequent in men than in women in most of these regions. Although the tremendous improvements in diagnosis and treatment technologies, the prognosis of advanced GC remains poor and the survival of affected patients is <40% even after a curative surgical resection and adjuvant therapy (4) . Hence, powerful biomarkers that can identify the early stages or patients at risk for GC, or predict the therapeutic responses of GC are urgently needed.
MicroRNA (miRNA) is a novel class of gene regulators that suppress protein expression through base pairing with the 3′-untranslated region (3′-UTR) of target messenger RNA. Accumulating evidence suggests that miRNAs play important roles in diverse biological processes and the dysfunction of miRNAs is involved in many diseases including cancer (5) . Although dysregulation of miRNAs has been observed in various types of cancers, the molecular mechanisms by which miRNAs modulate the process of carcinogenesis and the behavior of cancer cells are still largely unknown. Currently, altered miRNA expression patterns collected from different study cohorts have been observed in GC. Furthermore, several deregulated miRNAs (e.g. miR-21, miR-375, miR-124, miR-125b) have been shown to contribute to gastroesophageal carcinogenesis by altering expression of oncogenes and tumor suppressors to affect cell proliferation, apoptosis, and motility and invasion (6) . Meanwhile, a number of miRNAs, including circulating miRNAs, have been associated with tumor types or stages, or patient survival, and might be developed as diagnostic or prognostic markers (7) . Therefore, greater understanding of the roles of miRNAs in gastric carcinogenesis could provide insights into the mechanisms of tumor development and identify diagnostic biomarkers and therapeutic targets.
It has been reported that the members of miR-29 family are downregulated in a few tumor types and critical miRNAs with tumor suppressor functions (8) . They regulate the expression of many oncogenes, such as MCL-1, TCL-1, CDC42, p85α, DNMT3a and DNMT3b (9, 10) . Although a study described the roles of miR-29a in GC cell lines (11) , the accurate expression, mechanistic function and therapeutic roles of them in GC are largely unknown. In this study, we used Taqman probe stem-loop real-time PCR to accurately measure the levels of miR-29a, b and c in gastric carcinomas. Interestingly, we found that although the whole miR-29 family was downregulated in the GC, repressed miR-29c expression was the most significant and associated with aggressive phenotypes of GC. We also explored the molecular mechanisms underlying the tumor suppression role of these miRNAs and probably functional significance of this observation through in vitro and in vivo studies. from patients undergoing GC and collected at surgery, immediately snap frozen in liquid nitrogen and stored at −80°C until RNA extraction. GC pathological diagnosis was verified by at least two pathologists. Tumor and non-cancerous tissues were confirmed histologically by hematoxylin and eosin staining. The retrospective study was performed in these samples to analyze the expression level of mature miR-29s and the correlation of miR-29 family expression with clinicopathological variables of patients.
Materials and methods

Clinical samples
Cell culture GC cell lines, including HGC-27, BGC-823, SGC-7901, MKN-25 and MGC-803, were obtained from the American Type Culture Collection and cultured in Dulbecco's modified Eagle's medium RPMI-1640 with 10% fetal bovine serum (Gibco) at 37°C in 5% CO 2 cell culture incubator. 293T cells were obtained from American Type Culture Collection and cultured in Dulbecco's modified Eagle's medium with 10% fetal bovine serum.
RNA extraction and quantitative real-time PCR
Total RNA was extracted from the cell and tissues harvested using Trizol reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's instruction. The RNA was quantified by absorbance at 260 nm. To measure the level of miR-29a, b and c, quantitative real-time PCR (q-PCR) was performed by using Taqman probes (Invitrogen) in the Bio-Rad IQ5 real-time PCR system according to the manufacturer's instruction. The data were normalized using the endogenous U6 snRNA. The 2 −ΔΔCT method was used in the analysis of PCR data.
Constructs, reagents and assays
The 3′-UTR of the human CCND2 and matrix metalloproteinase-2 (MMP2) messenger RNA was cloned in between the Not1 and Xba1 sites of pGL-3 (Promega). Mutations of their 3′-UTR sequence were created by using a QuickChange Site-Directed Mutagenesis kit (Stratagene). Three luciferase reporters (pGL-3-29a/b/c PER) containing the miR-29 family consensus target sequence serve as the positive controls. miRNA mimics/inhibitors specifying miR-29 family and scramble control were obtained from Dharmacon (Chicago, IL). 293T cells were seeded onto 24-well plates (1 × 10 5 cells per well) the day before transfections. Cells (≈70% confluence) were transfected with pGL-3 firefly luciferase reports (50 ng per well), pRL-TK Renilla luciferase reports (10 ng per well) and miR-29 family mimics (50 nM). The pRL-TK vectors serve as the internal control. For HGC-27 and MGC-803 cells, pGL-3 firefly luciferase and pRL-TK luciferase reports were cotransfected into GC cells preseeded onto 24-well plates. All transfections were carried out in triplicate with Lipofectamine 2000 (Invitrogen). Cell lysates were prepared with Passive Lysis Buffer (Promega) 48 h after transfection, and luciferase activities were measured by using the Dual Luciferase Reporter Assay (Promega).
Oligonucleotides and transfection miR-29a, b and c mimics/inhibitors and negative control molecules (scramble control mimic and inhibitor) were obtained from Dharmacon (Austin, TX) and transfected with DharmFECT1 (Dharmacon) in HGC-27 or MGC-803 cells at a final concentration of 50 nM. Small interfering RNAs (siRNAs) (specifically for CCND2 or MMP2) and control siRNA were synthesized by GenePharma and transfected into HGC-27 or MGC-803 cells (100 nM) using Lipofectamine 2000 (Invitrogen). Medium was changed after 6 h, cells were cultured for 48 h and harvested for western blot analyses.
Northern blot
Northern blot analysis of miRNAs was performed as described previously (12) . The oligonucleotide probes' sequences were listed in Supplementary Table 2, available at Carcinogenesis Online.
Western blot
Whole cell lysate or nuclear extract was subjected to western blot analysis as described previously (13) . The following antibodies were used for western blot. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and β-actin were purchased from Santa Cruz Biotechnology. MMP2, CCND2, Rb and phosphorylated-Rb (Ser780) were purchased from Cell Signal Technology (CST) Company. Immunoblots were quantified by Image J software.
Cell proliferation and apoptosis assay
To measure the effect of miRNA mimics on cellular proliferation rates, cells were incubated in 10% CCK-8 (DOJINDO) diluted in normal culture media at 37°C until visual color conversion appears. Proliferation rates were determined at 24, 48, 72, 96 h posttransfection, and quantification was done on a microtiter plate reader (Spectra Rainbow; Tecan) according to the manufacturer's protocol. Apoptosis assay was performed on HGC-27 and MGC-803 cell lines at 72 h after transfection with either miR-29a, b, c mimics or control mimics using the Annexin V-FITC Apoptosis Detection kit I (BD Biosciences) according to the manufacturer's protocol and analyzed by using FACSCalibur Flow Cytometer (BECTON DICKINSON).
Cell invasion assay HGC-27 and MGC-803 cells were grown to 50-70% confluence and transfected with miR-29 family or control mimics. Twenty-four hours posttransfection, cells were seeded onto a Matrigel-coated membrane matrix (BD Biosciences) present in the insert of a 24-well culture plate. Fetal bovine serum was added to the lower chamber as a chemoattractant. After 24 h, the noninvading cells were gently removed with a cotton swab. Invasive cells located on the lower surface of chamber were stained with the 0.1% crystal violet (Sigma) and counted.
Immunohistochemistry
Human and mouse tumor tissues were made into paraffin sections and pretreated at 65°C for 2 h, followed by deparaffinization. Antigen retrieval was carried out before application of the primary antibodies (CCND2, 1:200, CST Company; MMP2, 1:200, CST Company; Ki-67, 1:100, DAKO) overnight at 4°C. As a negative control, sections were incubated with normal immunoglobulin G. Thereafter, slides were incubated for 2 h at room temperature with the secondary antibody conjugated to horseradish peroxidase (1:100; DAKO). Horseradish peroxidase activity was detected using the Liquid DAB+ Substrate Chromogen System (DAKO). Finally, sections were counterstained with hematoxylin and photographed.
Immunofluorescence staining HGC-27 cultures grown on glass coverslips were fixed in 4% paraformaldehyde at room temperature for 20 min. After washing in phosphate-buffered saline, cells were blocked and permeabilized in phosphate-buffered saline containing 2.5% goat serum and 0.1% Triton X-100 at room temperature for 90 min. Cells were incubated with human CCND2 or MMP2 antibodies (1:25; CST company) overnight at 4°C. Detection was with Alexa Fluor 488 goat anti-rabbit IgG (1:500; Invitrogen) at room temperature for 1 h. As a negative control, antibodies against rabbit immunoglobulin G were used. Cells were viewed and photographed with a Nikon TE2000 microscope.
Cell cycle assay
Cell cycle analysis was performed on HGC-27 and MGC-803 cells 72 h after transfection with either miR-29a, b, c mimics or control mimics as described previously (14) . Data was collected and processed by using the Modfit Cell Cycle Analysis Software.
In vivo studies
Animal xenograft model studies were performed according to institutional guidelines; 3 × 10 6 HGC-27 viable cells were injected subcutaneously into the posterior flanks of 6-week-old female nude mice, five mice per group. When tumors reached 50 mm 3 , miRNA mimics (miR-29a, b, c or scrambled control) diluted in Lipofectamine 2000 (Invitrogen) solution (100 nmol mimics in 100 μl total volume) were injected directly into the tumors, respectively. The tumors were injected every 3 or 4 days for a total of six times. Tumor diameters were measured after 10 days from injection and then every 3 days. At 28 days after injection, mice were killed and tumors were weighted after necropsy. Tumor volume was calculated as follows: length × width 2 × 1/2.
Statistics
The comparison of miR-29a/b/c expression between GC tissue and adjacent non-cancer tissue was evaluated by independent sample t-test (two tailed). Correlation of miR-29 family expression with patients' clinicopathological variables was evaluated by independent sample t-test (two tailed) or one-way analysis of variance, followed by Tukey post hoc test. All the analyses were completed by the software SPSS17.0 and P ≤ 0.05 was considered statistically significant.
Results
Members of miR-29 family were differently downregulated in GC
To accurately analyze the expression of miR-29 family in GC, q-PCR by using Taqman probes was conducted to measure the levels of miR-29a, b and c in 115 pairs of GC and adjacent non-neoplastic tissues. Here, the non-tumor samples from the macroscopic tumor margin (>5 cm from tumor tissues), which was further confirmed by pathologist for their normal origin that they do not have tumor cells, were isolated at the same time and used as the matched adjacent nonneoplastic tissues. The results showed that 39/115 (33.9%) of cases had reduced levels of miR-29a, 52/115 (45.2%) had reduced levels of miR-29b and 72/115 (62.6%) had reduced levels of miR-29c in GC tissues (C) compared with non-neoplastic gastric tissues (N) when the cutoff was set up as 1.5 ( Figure 1A ). Interestingly, miR-29c had the most reduced percentage in GC compared with non-tumorous tissues. Collectively, the data suggested that average expression of each member of miR-29 family was significantly attenuated in tumor tissues compared with adjacent non-neoplastic tissues (miR-29a, P < 0.05; miR-29b, P < 0.001; miR-29c, P < 0.001) ( Figure 1B ).
Low-level expression of miR-29c was associated with aggressive and progressive phenotypes of GC
To further investigate the clinicopathological and prognostic significance of miR-29 levels in patients with GC, the levels of miR-29 family in 77 pairs of GC tissues (including fully clinical information) were statistically analyzed. Correlation analysis showed that low-level expression of miR-29c in GC was significantly associated with a more extensive venous invasion (P = 0.05) ( Figure 1C , Supplementary in apoptotic cell fractions of HGC-27 and MGC-803 cells treated by miR-29a/b/c mimics for 48 h ( Figure 2D , Supplementary Figure 3C , available at Carcinogenesis Online). In addition, invasion assay was then performed to evaluate the effect of miR-29 family on the cell invasiveness in miR-29a/b/c overexpressing HGC-27 and MGC-803 cells and showed attenuated invasiveness of GC cells ( Figure 2E and F, Supplementary Figure 3D , available at Carcinogenesis Online). Together, these results indicated that miR-29 family could efficiently inhibit GC cell proliferation, promote cell apoptosis and repress cell invasiveness of GC cells in vitro, respectively.
miR-29 family targeted CCND2 and MMP2 genes in GC cells
Since miRNAs usually exert their function by negatively regulating the expression of their target genes and our results above indicate the tumor suppressive role of miR-29 family in GC, putative oncotargets of miR-29 family were predicted using target prediction programs, TargetScan, Pictar and miRanda. Our analysis revealed that CCND2 and MMP2 were potential targets of miR-29 family. The 3′-UTR of CCND2 or MMP2 messenger RNA contains a complementary site for the seed region of miR-29 family ( Figure 3A) . Although CCND2 was shown previously to be a target for miR-29 in rhabdomyosarcoma (15) , and MMP2 was demonstrated to be targeted by miR-29b in hepatocellular carcinoma (16) , the interaction between miR-29 and CCND2/MMP2 has not been experimentally validated in GC.
To determine whether CCND2 and MMP2 are direct targets of miR-29 family, wild-type and mutant 3′-UTR lacking miR-29 binding sites were cloned into the downstream of firefly luciferase coding region in pGL-3 luciferase reporter vector. The constructs were then cotransfected with pRL-TK and miR-29a, b, c or scramble mimics into 293T cells, respectively. The relative luciferase activity was reduced by 60 and 50% in pGL-3 vectors with wild-type CCND2 and MMP2 3′-UTR, respectively, but not in those with respective mutant 3′-UTRs ( Figure 3B ). More ever, the endogenous miR-29s indeed inhibited the luciferase activity of the pGL-3 vectors with wide-type CCND2 and MMP2 3'-UTR but did not affect the luciferase activity of the pGL-3 vectors with mutant 3'-UTR ( Figure 3C ) in HGC-27 and MGC-803, suggesting that miR-29 family cognate sites are essential for negative regulation of luciferase expression driven by CCND2-3′-UTR and MMP2-3′-UTR.
To confirm that miR-29 can indeed suppress expression of endogenous CCND2 and MMP2, HGC-27 and MGC-803 cells were transfected with miR-29a, b, c or scramble mimics, followed by detection of their protein levels. The protein levels of CCND2 and MMP2 were substantially decreased after ectopic overexpression of miR-29 family in HGC-27 and MGC-803 cell lines as evidenced by western blot assays ( Figure 3D ). On the other hand, knocking down of miR-29 family by anti-miR-29a, b or c in HGC-27 and MGC-803 cells increased protein levels of CCND2 and MMP2 ( Figure 3D ). Inhibition expression of miR-29 family upon transfection in these GC cell lines was confirmed by q-PCR (Supplementary Figure 4 , available at Carcinogenesis Online). Similarly, CCND2 and MMP2 immunoreactivities were diminished in HGC-27 cells transfected with the miR-29a/b/c mimics when compared with cells treated with the scramble mimic ( Figure 3E ). Taken together, these findings indicate that CCND2 and MMP2 can be negatively regulated by miR-29 family in GC cells.
miR-29 family regulated cell cycle through inhibiting CCND2 and p-Rb
CCND2 is one member of the cyclins participating in promoting the transition from G 1 phase of the cycle to S phase (17) . To verify whether miR-29 family inhibited tumorous phenotypes of GC cells through targeting CCND2, we first knocked down endogenous CCND2 through its specific siRNAs in HGC-27 and MGC-803 cells and analyzed the effect on cell proliferation ( Figure 4A ). We observed that downregulating CCND2 inhibited the cell growth and G 1 /S transition in these cells ( Figure 4B and C) . Previous studies indicated that CCND2 functions through regulating the phosphorylation level of Rb to regulate the cell cycle (18, 19) . To analyze whether miR-29 family affects cell cycle progression through inhibiting CCND2/p-Rb, we transfected miR-29 mimic into HGC-27 and MGC-803 cells and measured the levels of p-Rb and total Rb. A decreased p-Rb level was detected in GC cells transfected with miR-29 mimics as compared with the cells transfected with the scramble mimics, whereas the level of total Rb remained consistent ( Figure 4D ). Meanwhile, we found that CCND2 siRNAs also promoted cell apoptosis of HGC-27 and MGC-803 cells ( Figure 4E ). These data indicated that miR-29 family could inhibit cell proliferation and cell cycle progression through downregulating p-Rb activity.
Inhibition of miR-29 targets decreased GC cell invasiveness
Our data suggested that miR-29 family might regulate tumor cell metastasis in vitro by seeding on 3′-UTR sites of their targets. To investigate whether miR-29 family affects cell invasiveness by targeting CCND2 and MMP2 in GC cells, we used specific siRNAs to knock down endogenous CCND2 and MMP2 ( Figure 4F ) and examine cell invasiveness of HGC-27 and MGC-803 cells. We observed that siRNAs targeting CCND2 and MMP2 inhibited the invasiveness of HGC-27 and MGC-803 cells, respectively ( Figure 4G ). These results suggest that miR-29 family regulates CCND2 and MMP2, which affect GC cell invasiveness.
miR-29 family targeting CCND2 and MMP2 was clinically validated in GC patients
To address the functional relevance of miR-29 family and their target levels in human GC patients, we analyzed the expression of miR29a/b/c, CCND2 and MMP2 expression in four pairs of GC and their corresponding adjacent non-cancer tissues. Northern blot was first performed to evaluate the expression of miR-29 family in these tissues and showed markedly reduced miR-29a, b and c in GC compared with the corresponding controls ( Figure 5A ). Immunoblot analysis was simultaneously conducted in the same tissues and indicated that the levels of these proteins were evidently upregulated in GC as compared with the matching non-neoplastic tissues ( Figure 5B ).
Meanwhile, immunohistochemistry was used to assess the expression of CCND2 and MMP2 in the same GC tissues. Consistent with the immunoblot findings, CCND2 and MMP2 staining was also increased in GC tissues as compared with the matching normal gastric tissues ( Figure 5C ). To further validate our findings, the levels of miR-29 family, CCND2 and MMP2 were measured in additional 16 of human primary GC and pair-matched peritumoral gastric tissues (Supplementary Figure 5A and B, available at Carcinogenesis Online). Comparison of miR-29a/b/c levels and protein levels corresponding to CCND2 and MMP2 in GC exhibited significantly inverse correlation between CCND2 and miR-29c (r 2 = 0.2248, P = 0.0347), and inverse correlation between MMP2 and miR-29a (r 2 = 0.1995, P = 0.0483), or miR-29c (r 2 = 0.3593, P = 0.0052) ( Figure 5D ). Collectively, these findings provide strong evidence that CCND2 and MMP2 are direct targets of miR-29 family in GC.
miR-29 family inhibited the growth of HGC-27-engrafted tumors
Our above findings indicated that miR-29 family was potential therapeutic targets in GC. To investigate the therapeutic effect of miR-29s on gastric tumorigenicity in vivo, ~3 × 10 6 HGC-27 cells were inoculated subcutaneously in posterior flanks of immunocompromised 'nude' mice. When tumors reached 50 mm 3 , synthetic miR-29a/b/c or scrambled oligonucleotides were injected directly into the tumors. The tumors were injected every 3 days for a total of six times ( Figure 6A ). After 4 weeks, we found that injection with miR-29s inhibited the growth of HGC-27-engrafted tumors with respect to scrambled oligonucleotides-treated tumors ( Figure 6B ). In agreement with the tumor growth curve, the volumes and weights of tumors treated by miR-29 mimics were significantly lower than scrambled mimics-injected tumors ( Figure 6C and D) . In view of these observations, we reasoned that increased levels of miR-29s in mouse tumors after injection with mimics might affect tumor cell proliferation. To address this point, immunohistochemical analysis was used to measure the protein levels of Ki-67 in the tumor tissues, showing decreases of Ki-67 in miR29a/b/c-injected tissues ( Figure 6E ). These data indicated that introduction of miR-29a, b and c remarkably inhibited the tumorigenicity of HGC-27 cells in the nude mouse xenograft model. Moreover, we also performed immunohistochemistry to detect the expression of CCND2 and MMP2 in randomly selected xenograft mouse tumors and found that miR-29 mimics-injecting tumors expressed lower levels of CCND2 and MMP2 than scramble controls ( Figure 6F) . Thus, the possibility that introduction of miR-29 mimics may contribute to GC control provides a novel method for GC therapy.
Discussion
Our recent study reported high frequency of miR-29a downregulation in human acute myeloid leukemia and demonstrated its potential tumor suppressor function in acute myeloid leukemia (20, 21) . This article showed that all members of miR-29 family were downregulated in GC and miR-29c was more significant than miR-29a or 29b as a signature miRNA of GC. Furthermore, our results indicated that miR-29 family directly targeted CCND2 and inhibited Rb phosphorylation activity, leading to repressed cell proliferation, arrested G 1 /S transition and enhanced cell apoptosis in GC cells. Our results also indicated that miR-29 family directly targeted CCND2 and MMP2 to inhibit cell invasiveness in GC cells. Moreover, our investigation for the expression of CCND2, MMP2 and miR-29 family in 20 GC patients indicated that there was an inverse correlation between miR-29 family and CCND2/MMP2 levels. Importantly, overexpressing miR-29 family ameliorated progression of GC in an established experimental xenograft model, respectively.
An emerging body of evidence suggests that miRNAs serve as importantly therapeutic targets in a wide range of complex human diseases by targeting multiple transcripts (22, 23) . We argued that to identify key regulatory miRNAs in GC, it would be necessary to examine accurate miRNA expression patterns in an unbiased manner. Downregulation of the miR-29 family has been reported in acute myeloid leukemia (24) , chronic lymphocytic leukemia (25) , lung cancer (26, 27) and nasopharyngeal cancer (28) , and a possible role of miR-29 as a tumor suppressor has been hypothesized. However, the expression and function of miR-29 family was not well known in GC. Accordingly, we elaborately examined expression properties of miR-29 family through q-PCR in samples obtained from GC patients. Our experimental design identified downregulation of miR29a, b and c as marked signatures in GC. Although a few studies indicated that miR-29 family might act as oncogenes in metastatic breast cancer and indolent lymphocytic leukemia (27, 29) , downregulated miR-29a or 29b was demonstrated to be significant in most of cancers, including our findings. Interestingly, we found that the level of the miR-29c was able to monitor tumor progression, implying that lower level of the miRNA would potentially predict more aggressive and progressive phenotypes of the GC patients. Actually, miR-29c was identified as a tumor suppressor gene rather than miR-29a or 29b in a few types of cancers, such as nasopharyngeal carcinomas, chronic lymphocytic leukemia and esophageal squamous cell carcinoma (28, 30, 31) . The result suggested that miR-29c might exert more important function and possess specific processing mechanism in cancer progression.
CCND2 gene encoded a protein termed G 1 /S-specific cyclin-D2, which belongs to the highly conserved cyclin family. CCND2 forms a complex with CDK4 or CDK6 and functions as a regulatory subunit of them, whose activity is required for cell cycle G 1 /S transition (32, 33) . This protein has been shown to interact with Rb and regulate the phosphorylation of Rb (34) . A previous study has indicated that CCND2 was a target for miR-29 family in rhabdomyosarcoma (15) . However, the interaction between miR-29s and CCND2 has not been experimentally investigated in GC. We here performed in vitro and in vivo studies to demonstrate that miR-29 family can regulate GC cell proliferation and G 1 /S transition through targeting CCND2, then modulating the level of p-Rb. MMP2 is involved in the breakdown of extracellular matrix in normal physiological processes as well as in disease processes, such as metastasis of tumor cells. MMP2 has been shown to be a direct target of miR-29b in prostate cancer and hepatocellular carcinoma (16) . We have demonstrated in vitro that all the members of miR-29 family inhibited cell invasiveness through targeting MMP2 in GC. Meanwhile, we also demonstrated that miR-29 family inhibited cell invasiveness through targeting CCND2 in GC cells.
Upregulation of CCND2 and MMP2 has been observed in different types of malignancy, including GC (35) . We have also analyzed the correlation between miR-29 family expression and protein expression of their targets in 20 primary GC samples. Consistent with the cell line data, CCND2 and MMP2 were enriched in the primary GC tissues that inversely correlated to miR-29a, 29b or 29c levels. This result was also observed at the immunostaining in a few primary GC samples. However, further studies using large numbers of primary GC samples will be needed to confirm this interaction.
Although a few studies have tested whether members of miR-29 family could reduce tumorigenicity in a xenograft model, we also tested the tumor-suppressive role of miR-29 family in vivo through direct miRNA mimics injection and found that miR-29a/b/c significantly inhibited the growth of GC cells, respectively. Further immunohistochemistry analysis in xenograft carcinoma tissues demonstrated the negative regulation of miR-29 to CCND2 and MMP2, suggesting that miR-29a, b, and c might be better therapeutic choices in GC. In conclusion, a better knowledge of miR-29a/b/c functions, their interrelationships with these cellular processes and the already available treatments against unwanted proliferation can generate new approaches, such as combined therapies, in which the manipulation of miRNA expression can play a pivotal role.
Taken together, our work demonstrated that miR-29 family was differentially expressed in GC and acted as tumor suppressor genes by regulating critical oncogenic targets through in vitro and in vivo experiments. Reintroducing miR-29a/b/c expression downmodulated CCND2 and MMP2, which induced cell apoptosis, suppressed cell invasion and dampened cell growth in GC cells, thereby suggesting miRNA-based therapeutic pattern in GC.
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